• Molecular NameQuinestrol
  • Synonym17-alpha-Ethinylestradiol 3-cyclopentyl ether; 17alpha-Ethynylestradiol 3-cyclopentyl ether; Estradiol-17-beta 3-cyclopentyl ether; Quinestrolo [dcit]; Quinestrolum [inn-latin]
  • Weight364.529
  • Drugbank_IDDB04575
  • ACS_NO152-43-2
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)4.89
  • pkaN/A
  • LogD (pH=7, predicted)4.89
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-6.18
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors1
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds3
  • TPSA29.46
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA synthetic estrogen used in hormone replacement therapy, and occasionally to treat breast cancer and prostate cancer.
  • Absorption_valueN/A
  • Absorption (description)Absorbed following oral administration.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMetabolized principally to the parent compound, ethinyl estradiol. Ethinyl estradiol is metabolized in the liver. Quantitatively, the major metabolic pathway for ethinyl estradiol, both in rats and in humans, is aromatic hydroxylation, as it is for the natural estrogens.
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A